Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer

NCT01498562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Gefitinib and Nimotuzumab
DRUG: Gefitinib

Sponsor

Yonsei University